[
    [
        {
            "time": "",
            "original_text": "医药行业2020Q3持仓分析：医药仓位有所回落 紧握核心资产",
            "features": {
                "keywords": [
                    "医药行业",
                    "2020Q3",
                    "持仓分析",
                    "仓位回落",
                    "核心资产"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药行业2020Q3持仓分析：医药仓位有所回落 紧握核心资产",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业上市公司2020年三季报小结：疫情影响逐渐消退 关注高成长龙头+细分冠军",
            "features": {
                "keywords": [
                    "医药生物",
                    "2020年三季报",
                    "疫情影响",
                    "消退",
                    "高成长",
                    "龙头",
                    "细分冠军"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业上市公司2020年三季报小结：疫情影响逐渐消退 关注高成长龙头+细分冠军",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "阿斯利康：与牛津研发的新冠疫苗年内启动中国临床试验",
            "features": {
                "keywords": [
                    "阿斯利康",
                    "牛津",
                    "新冠疫苗",
                    "中国临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "阿斯利康：与牛津研发的新冠疫苗年内启动中国临床试验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "阿斯利康: 新冠疫苗将于年内在中国启动一、二期临床实验，国内试验样品将由康泰生物负责生产",
            "features": {
                "keywords": [
                    "阿斯利康",
                    "新冠疫苗",
                    "中国",
                    "临床实验",
                    "康泰生物"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "阿斯利康: 新冠疫苗将于年内在中国启动一、二期临床实验，国内试验样品将由康泰生物负责生产",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "阿斯利康(AZN.US)：年内在中国启动新冠疫苗临床实验 或明年申请上市",
            "features": {
                "keywords": [
                    "阿斯利康",
                    "AZN.US",
                    "新冠疫苗",
                    "中国",
                    "临床实验",
                    "申请上市"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "阿斯利康(AZN.US)：年内在中国启动新冠疫苗临床实验 或明年申请上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]